Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin with or without ezetimibe pre-treatment before elective PCI in NSTE-ACS
ChiCTR1900026762Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of atorvastatin and ezetimibe in acute coronary syndrome (ACS) and non–ST-segment elevation acute coronary syndrome (NSTE-ACS), sponsored by First Hospital of China Medical University. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
atorvastatinezetimibe
03
Conditions
acute coronary syndrome (ACS)non–ST-segment elevation acute coronary syndrome (NSTE-ACS)
Beyond the preview
Go deeper on ChiCTR1900026762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026762.